Shabsigh Ahmad, Bochner Bernard H
Division of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, 353 E. 68th Street, New York, NY 10021, USA.
World J Urol. 2006 Nov;24(5):489-98. doi: 10.1007/s00345-006-0122-y.
Bladder cancer is a common genitourinary malignancy that demonstrates a great variation in risk of tumor recurrence and progression following treatment. The dramatic differences in clinical behavior dictate vastly differing treatments, which may range from simple surveillance to combination radical surgery with systemic chemotherapy. For non-muscle invasive bladder cancer prediction of the risk of recurrence and progression is necessary to assess the need for intravesical therapy and possible early cystectomy. In contrast, prediction of advanced disease response to primary treatment such as cystectomy and the response to systemic chemotherapy plays an important role in treatment assignment for patients with muscle invasive disease. To estimate these risk traditional risk grouping schemes such as the present TNM staging system has been used to guide patient treatment. More recently, improved prognostic tools such as nomograms have been developed to provide a more accurate assessment of outcomes. Clinicians are enthusiastically working to utilize these statistical methods in bladder cancer. We summarize the current status of outcome predictive models for bladder cancer; and focus particularly on the ability of nomograms to predict disease recurrence, progression, and patient survival.
膀胱癌是一种常见的泌尿生殖系统恶性肿瘤,治疗后肿瘤复发和进展风险差异很大。临床行为的巨大差异决定了治疗方法大不相同,从简单的监测到根治性手术联合全身化疗不等。对于非肌层浸润性膀胱癌,预测复发和进展风险对于评估膀胱内治疗的必要性以及可能的早期膀胱切除术至关重要。相比之下,预测晚期疾病对诸如膀胱切除术等初始治疗的反应以及对全身化疗的反应,在肌层浸润性疾病患者的治疗分配中起着重要作用。为了估计这些风险,传统的风险分组方案如目前的TNM分期系统已被用于指导患者治疗。最近,已开发出如列线图等改进的预后工具,以提供更准确的预后评估。临床医生正积极致力于在膀胱癌中运用这些统计方法。我们总结了膀胱癌预后预测模型的现状;并特别关注列线图预测疾病复发、进展和患者生存的能力。